Ono enters AI collaboration with Iktos

Japan’s Ono Pharmaceutical (TYO: 4528) has entered into a collaboration agreement with privately-held French artificial intelligence (AI) company Iktos to discover and develop novel small-molecule compounds using Iktos’ unique AI drug discovery technology.

Under the terms of the agreement, Iktos will apply its AI technology platform and know-how, helping to bring new insights and directions into the drug discovery process based on a comprehensive data-driven chemical structure generation technology complementing Ono’s drug discovery program to expedite the identification of novel small molecules against therapeutic targets selected by Ono. Ono will acquire exclusive worldwide rights to develop and commercialize small molecule compounds discovered in the collaboration.

Research funding and milestones for Iktos